Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial - Curtis, JR; Yamaoka, K; Chen, YH (Ann Rheum Dis, 2023)
et al.